Aminoindazole PDK1 Inhibitors: A Case Study in Fragment-Based Drug Discovery.Medina, J.R., Blackledge, C.W., Heerding, D.A., Campobasso, N., Ward, P., Briand, J., Wright, L., Axten, J.M.
(2010) ACS Med Chem Lett 1: 439-442
- PubMed: 24900229
- DOI: https://doi.org/10.1021/ml100136n
- Primary Citation of Related Structures:
3NUS, 3NUU, 3NUY
- PubMed Abstract:
Fragment screening of phosphoinositide-dependent kinase-1 (PDK1) in a biochemical kinase assay afforded hits that were characterized and prioritized based on ligand efficiency and binding interactions with PDK1 as determined by NMR. Subsequent crystallography and follow-up screening led to the discovery of aminoindazole 19, a potent leadlike PDK1 inhibitor with high ligand efficiency. Well-defined structure-activity relationships and protein crystallography provide a basis for further elaboration and optimization of 19 as a PDK1 inhibitor.
Molecular Discovery Research, Screening and Compound Profiling, GlaxoSmithKline, Research Triangle Park, North Carolina 27709.